Pregled bibliografske jedinice broj: 699106
Limited effect or renal denervation in resistant hypertension
Limited effect or renal denervation in resistant hypertension // Nephrology Dialysis Transplantation 2014 ; 29 (Suppl. 3): iii87-iii87.
Amsterdam, Nizozemska, 2014. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 699106 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Limited effect or renal denervation in resistant hypertension
Autori
Baotić, Ines ; Vidjak, Vinko ; Prkačin, Ingrid ; Bulum, Tomislav
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Nephrology Dialysis Transplantation 2014 ; 29 (Suppl. 3): iii87-iii87.
/ - , 2014
Skup
51st ERA-EDTA Congress
Mjesto i datum
Amsterdam, Nizozemska, 31.05.2014. - 03.06.2014
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
renal denervation; resistant hypertension
Sažetak
Renal Denervation (RDN), an endovascular catheter- based intervention, is being applied as a novel concomitant treatment of drug-resistant hypertension (rHT). However, with underpowered efficacy and safety data currently available. The aim of this study was to evaluate the duration of the blood pressure (BP) lowering effect of RDN and reduction of antihypertensive drug classes needed after intervention. Office BP measurements at 1, 3 and 6 months follow-up visits were compared to baseline values in 7 patients with rHT. Also, the number of antihypertensive drug classes before and 6 months after RDN were evaluated. At baseline, values were 62 ± 6 years for age, 184 ± 21 mmHg and 106 ± 26 mmHg for systolic and diastolic BP, respectively ; and 6.7 1 for number of antihypertensive drug classes. One, 3 and 6 months after RDN, office SBP values were significantly lower (144 ± 13 mmHg, 140 ± 17 mmHg and 141 ± 15 mmHg, respectively ; P < 0.001). However, with no significant reduction in DBP values at 1, 3 and 6 months after RDN (81 ± 6 mmHg, 82 ± 9 mmHg and 79 ± 9 mmHg, respectively ; P < 0.05). Six months after RDN the number of antihypertensive drug classes required was 6.5 1 which was not statistically different from baseline. The sustained reduction of office SBP was observed during 6 months after the RDN. For better understanding the efficacy and safety of RDN we need well structured randomized clinical trials in patients with rHT and various co- morbidities. Also, further meta-analysis to evaluate the optimal target population and importance of RSD as rHT treatment.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE